ClinicalTrials.gg
RecruitingNCT06755840Updated Apr 3, 2025

Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study

An observational study in Sleep Disordered Breathing (SDB), Sleep Apnea and Cardiometabolic Diseases, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Xiangya Hospital of Central South University · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
15,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Sleep Apnea Syndromes with a site in China — 9 open to participants now, 10 under way, 1 of them phase 3. Sleep Apnea Syndromes · China.

Planned enrollment
2nd of 14
15,000 · median 353
Started
2025
with 3 others
Observational
14 of 26
6 open now
Registered
19th of 26
by date

Among the 26 studies in Sleep Apnea Syndromes with a site in China, this one is the 2nd largest by planned enrollment of the 14 observational ones that give a count, is one of 4 that started in 2025, is one of 14 observational ones, and was the 19th registered.

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

9 of the 26 studies in Sleep Apnea Syndromes with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Sleep Apnea Syndromes with a site in China, or all of them as a file.
02

Study summary

Sleep disordered breathing (SDB) is one of the most common sleep disorders, including obstructive sleep apnea (OSA), central sleep apnea (CSA), sleep-related hypoventilation, hypoxemia, etc., with OSA being the most prevalent. Also, SDB shows high comorbidities with multisystem diseases. Furthermore, compared to patients with pure SDB, those comorbid with SDB and other disorders like cardiometabolic dysfunction and cognitive impairment experience poorer quality of life, higher rate of disease progression and mortality, and a greater economic burden. Currently, there are limited cohorts to study the associations between SDB and multisystem diseases. The aim of this study is to establish an ambispective clinical cohort for SDB in Xiangya hospital from central-south China (Xiangya Sleep Disordered Breathing Cohort, Xiangya SDB cohort) including retrospective part and prospective part, which covers multi-dimensional data of sleep monitoring, demographic, daily behaviors, clinical manifestations and comorbidities status, life quality, treatment information and evaluation, etc. by self-reported questionnaires and objective assessments and tests. Besides, whole peripheral blood is drawn for following biomarkers study and omics analysis. The main goal is to achieve precise management of SDB and related multimorbidity, containing to early identify risk individuals for multisystem impairment, significantly improve their prognosis and ultimately enhance overall health. In detail: first, to reveal how multisystem impairment related to SDB evolves; second, to identify which indicators closely involve system dysfunction due to SDB; third, to build an efficient model and a cost-effective platform to screen high-risk population and tract therapeutic effect.

Read the detailed description

This study will be designed as a non-interventional and ambispective cohort study incorporating a retrospective part (Xiangya SDB cohort-Retrospective part) and a prospective part (Xiangya SDB cohort-Prospective part). It has received approval from the Medical Ethics Committee of Xiangya Hospital Central South University on August 21, 2024. The study will collect basic information, sleep parameters, clinical manifestation, comorbidities status, life quality and mortality from participants, through subjective and objective questionnaires, physical examinations, sleep monitoring, laboratory tests (blood routine test, serum biochemistry, myocardial enzymes, etc.), imaging tests (CT, echocardiogram, etc.) and other specific tests (pulmonary function test, etc.), as well as subsequent annual visits.

Xiangya SDB cohort-Retrospective part: The participants in this part primarily include individuals who completed sleep monitoring at the Sleep Medicine Center of Xiangya Hospital of Central South University from January 1, 2016 to January 14, 2025. Relevant comorbidities diagnoses and treatment data will be extracted from electronic health records. Meanwhile, questionnaires, physical examinations, laboratory tests, imaging tests, echocardiograms and pulmonary function tests, etc. will also be accessed to evaluate multisystem function and impairments. Subsequent long-term visits will collect all-cause and specific-cause death and evaluate the improvement and/or progression of cardiovascular, metabolic, respiratory, nervous, mental and neoplastic disorders, with supplementary data gathered from historical records.

Xiangya SDB cohort-Prospective part: The prospective cohort will begin enrolling participants from January 15, 2025, with their first sleep monitoring and the date of enrollment as the baseline visit. Concurrently, their basic information, clinical data, questionnaires related to sleep habits and quality, comorbidities status, physical examination, hospital laboratory and imaging data and pulmonary function test, etc. will also be collected. Subsequently, participants will be followed up every 12 to 24 months through phone calls, home visits or hospital visits.

Notably, participants signing informed consent will have an additional 10 ml of peripheral blood collected during routine clinical care (outpatient visits, hospitalizations, follow-ups, etc.) for biomarkers and multi-omics research. The follow-up visits will include: 1) death event and the causes; 2) relevant questionnaires and tests described as above to assess the function and diseases disease status of each comorbid system.

03

Conditions studied

  • Sleep Disordered Breathing (SDB)
  • Sleep Apnea
  • Cardiometabolic Diseases
  • Multimorbidity
  • Neurodegenerative Diseases

Keywords

  • sleep disordered breathing
  • obstructive sleep apnea
  • central sleep apnea
  • cardiovascular diseases
  • metabolic diseases
  • respiratory diseases
  • nervous system diseases
  • mental disorders
  • neoplasms
  • multimorbidity
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

participants who complete at least one overnight sleep monitor session in the Sleep Medicine Center of Xiangya hospital Central South University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1) Participants who were suspected of sleep disordered breathing must complete at least one overnight sleep monitoring at the Sleep Medicine Center at Xiangya Hospital.
  • 2) Participants can finish any assessment for each comorbid system by questionnaires, scales, physical examinations and tests, etc. independently or with the assistance.
  • 3) Participants agreed to participate in this study with signing an form.

Exclusion criteria

Exclusion Criteria:

  • Participants who refused to participate in this study or whose clinical data was lost.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
15,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Death event

    Death due to any cause or specific cause

    Time frame: From participants agreed to participate in this study until the date of death from any or specific cause or the end of the study, whichever came first, assessed up to 10 years.

Secondary outcomes

  1. Life quality as measured by the 12-item short form health survey (SF-12)

    The seven situations of SF-12 include physical function, role limitations due to physical health or emotional problems, bodily pain, general health perceptions, vitality, and social function. The scoring criteria for the SF-12 scale is based on a percentage system, where higher scores indicate better quality of life.

    Time frame: Through study completion, an average of 2 years

  2. Daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS)

    ESS is intended to assess sleepiness liability (from 0 to 3 score) across eight different situations, the higher score indicates more likely to sleepiness.

    Time frame: Through study completion, an average of 2 years

  3. Sleep quality and behavior as measured by the Pittsburgh Sleep Quality Index (PSQI)

    The seven different dimensions of PSQI include sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. The total score of PSQI ranges from 0 to 21 and the higher score indicates poorer sleep.

    Time frame: Through study completion, an average of 2 years

  4. Rapid Eye Movement Sleep Behavior Disorder Questionnaire Hong Kong (RBD-HK) applied for RBD screening

    RBD-HK mainly accesses symptoms and severity of RBD.

    Time frame: Through study completion, an average of 2 years

  5. Cognitive function and impairment as measured by Ascertain Dementia 8 (AD8)

    AD8 is intended to access cognitive function and impairment through eight concise questions. A score of 2 or above indicates cognitive impairment.

    Time frame: Through study completion, an average of 2 years

  6. Number of participants with cardiometabolic diseases or events

    The occurrence of cardiometabolic diseases or events (e.g. hypertension, heart failure, ACS and DM, etc.) are identified by self-report or their electronic health records and tests (e.g. blood pressure, blood glucose, lipids and hormone levels, echocardiogram, ECG etc.)

    Time frame: Through study completion, an average of 2 years

  7. Number of participants with respiratory diseases or events

    The occurrence of respiratory diseases or events (e.g. COPD and asthma, or hospitalization due to exacerbation, etc.) are identified by self-report or their electronic health records and tests (e.g. lung function test parameters, etc.)

    Time frame: Through study completion, an average of 2 years

  8. Number of participants with nervous system and mental diseases and status

    The occurrence of nervous system and mental diseases and status (e.g. stroke, dementia, Parkinson's disease, depression, etc.) are identified by participants self-report or their electronic health records.

    Time frame: Through study completion, an average of 2 years

  9. Number of participants with digestive system diseases or events

    The occurrence of digestive diseases (e.g. GERD, crohn's disease, ulcerative colitis, etc.) are identified by participants self-report or their electronic health records

    Time frame: Through study completion, an average of 2 years

  10. Number of participants with kidney diseases or events

    The occurrence of kidney diseases or events (e.g. CKD etc.) are identified by self-report or their electronic health records and tests (e.g. eGFR etc.)

    Time frame: Through study completion, an average of 2 years

  11. Number of participants with neoplasms diseases or events

    The occurrence of neoplasms diseases or events (e.g. any type of tumor, adverse events, etc. ) are identified by self-report or their electronic health records

    Time frame: Through study completion, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2030, 71 months after the start.

Of 130 non-industry observational studies under Sleep Apnea Syndromes, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 83. This study's planned 71 months is above that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 15 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Jan 1, 2025
StartActual
Jan 15, 2025
Primary completionEst.
Dec 31, 2030
CompletionEst.
Oct 31, 2035
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06755840
Responsible party
Sponsor
First posted
Jan 1, 2025
Start date
Jan 15, 2025
Primary completion
Dec 31, 2030 (estimated)
Completion
Oct 31, 2035 (estimated)
Last update
Apr 3, 2025

Study contacts

Yuan Zhang
Contact
zhangyuan9194@csu.edu.cn
86-0731-84327029

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion